Autoantigens Plus Interleukin-10 Suppress Diabetes Autoimmunity

被引:17
|
作者
Denes, Bela [1 ,2 ]
Fodor, Istvan [1 ]
Langridge, William H. R. [1 ]
机构
[1] Loma Linda Univ, Ctr Hlth Dispar & Mol Med, Dept Biochem & Microbiol, Loma Linda, CA 92350 USA
[2] Cent Vet Inst, Dept Immunol, Budapest, Hungary
基金
美国国家卫生研究院;
关键词
TOXIN B-SUBUNIT; GLUTAMIC-ACID DECARBOXYLASE; ANTIGEN-PRESENTING CELLS; REGULATORY T-CELLS; CHOLERA-TOXIN; NOD MICE; VACCINIA VIRUS; GENE-TRANSFER; MUCOSAL IMMUNITY; TRANSGENIC EXPRESSION;
D O I
10.1089/dia.2009.0116
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recombinant vaccinia virus (rVV) strains expressing the immunomodulatory cholera toxin B subunit (CTB) fused to the autoantigen glutamic acid decarboxylase (GAD) or the immunosuppressive cytokine interleukin-10 (IL-10) were independently able to generate only low levels of immune suppression of type 1 diabetes mellitus (T1DM). Here we suggest that a vaccinia virus (VV)-mediated combination of CTB::GAD fusion and IL-10 proteins promises a effective and durable immunotherapeutic strategy for T1DM. Methods: To explore this hypothesis, a CTB::GAD fusion gene was co-delivered with a gene encoding IL-10 by rVV infection (rVV-CTB::GAD+rVV-IL10) into 5-7-week-old non-obese diabetic (NOD) mice. The mice were assessed for vaccine protection against development of hyperglycemia from 12 to 64 weeks of age by assessment of pancreatic inflammation (insulitis) and splenocyte-secreted interferon-gamma and IL-10 cytokine levels. Results: By 36 weeks of age, from 54% to 80% of the mice in the negative control animal groups (either mock-infected or inoculated with unrelated plasmid or VV) had developed hyperglycemia. Similarly, no statistically significant improvement in protection against diabetes onset was achieved by inoculation with VV expressing CTB::GAD or IL-10 independently. Surprisingly, only 20% of mice co-inoculated with rVV-CTB::GAD+rVV-IL10 developed hyperglycemia by 28 weeks of age. Other treatment groups developed hyperglycemia by 32-36 weeks. After 36 weeks, diabetes incidence no longer increased in any groups until the end of experiment at 64 weeks of age. Histological analysis of pancreatic tissues of hyperglycemic mice revealed high levels of intra-islet insulitis. Analysis of insulitis at termination of the experiment showed that euglycemic mice co-inoculated with VV expressing CTB::GAD and IL-10 had more effectively reduced inflammation in comparison with the other groups. Conclusions: A combinatorial vaccination strategy based on VV co-delivery of genes encoding the immuno-enhanced autoantigen CTB::GAD and the anti-inflammatory cytokine IL-10 can maintain effective and durable euglycemia and immunological homeostasis in NOD mice with prediabetes.
引用
收藏
页码:649 / 661
页数:13
相关论文
共 50 条
  • [21] Interleukin-10 in the intestine
    Schreiber, S
    GUT, 1997, 41 (02) : 274 - 275
  • [22] Autoimmunity to heat shock protein 60 and antigen-specific production of interleukin-10
    Yi, YJ
    Yang, X
    Brunham, RC
    INFECTION AND IMMUNITY, 1997, 65 (05) : 1669 - 1674
  • [23] DIRECTLY REPROGRAMMED OSTEOBLASTS GENETICALLY ENGINEERED TO PRODUCE INTERLEUKIN-10 SIGNIFICANTLY SUPPRESS OSTEOCLASTGENESIS
    Fujioka, K.
    Kishida, T.
    Kukida, Y.
    Nagahara, H.
    Fujii, W.
    Murakami, K.
    Seno, T.
    Yamamoto, A.
    Kohno, M.
    Mazda, O.
    Kawahito, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 794 - 794
  • [24] INTERLEUKIN-10 TREATMENT CAN SUPPRESS STROMAL KERATITIS INDUCED BY HSV-1
    TUMPEY, T
    ELNER, V
    OAKES, JE
    LAUSCH, RN
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1994, 35 (04) : 1332 - 1332
  • [25] Targeting of interleukin-10 receptor by a potential human interleukin-10 peptide efficiently blocks interleukin-10 pathway-dependent cell proliferation
    Chang, Chun-Chun
    Liu, Cheng-Der
    Pan, Sheng-Feng
    Huang, Wei-Han
    Peng, Chih-Wen
    Hsu, Hao-Jen
    TZU CHI MEDICAL JOURNAL, 2020, 32 (03): : 245 - 253
  • [26] Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients
    Lowe, PR
    Galley, HF
    Abdel-Fattah, A
    Webster, NR
    CRITICAL CARE MEDICINE, 2003, 31 (01) : 34 - 38
  • [27] Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells
    Ledeboer, A
    Brevé, JJP
    Wierinckx, A
    van der Jagt, S
    Bristow, AF
    Leysen, JE
    Tilders, FJH
    Van Dam, AM
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 16 (07) : 1175 - 1185
  • [28] Association of Interleukin-10 Methylation Levels With Gestational Diabetes in a Taiwanese Population
    Kang, Jessica
    Lee, Chien-Nan
    Li, Hung-Yuan
    Hsu, Kai-Han
    Wang, Shu-Huai
    Lin, Shin-Yu
    FRONTIERS IN GENETICS, 2018, 9
  • [29] Interleukin-10 plasmid construction and delivery for the prevention of type 1 diabetes
    Lee, Minhyung
    Park, Hyewon
    Youn, Jeehee
    Oh, Eun Taex
    Ko, Kyungsoo
    Kim, Sungwan
    Park, Yongsoo
    IMMUNOLOGY OF DIABETES IV: PROGRESS IN OUR UNDERSTANDING, 2006, 1079 : 313 - 319
  • [30] Interleukin-10 attenuates renal injury after myocardial infarction in diabetes
    Fan, Xiaoming
    Zhang, Xiaolu
    Liu, Lijun C.
    Kim, Annes Y.
    Curley, Sean P.
    Chen, Xiaohuan
    Dworkin, Lance D.
    Cooper, Christopher J.
    Gupta, Rajesh
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (05) : 1233 - 1242